Evaluation of protein Z plasma level in beta-thalassemia major patients in Ahvaz city in Iran

Abstract

OBJECTIVES: Thrombotic episodes occurred frequently in beta-thalassemia major (BTM) patients, leading to hypercoagulability of plasma. Protein Z (PZ) is a vitamin-K-dependent anti-coagulation factor that plays a role in the human homeostatic process. The objective of the current study is to investigate the distribution pattern of PZ plasma concentrations between BTM patients and the normal population in Ahvaz city, the center of Khuzestan province, southwest of Iran.

MATERIAL and METHODS: Forty confirmed BTM patients and 40 healthy volunteers were evaluated for complete blood count (CBC) indices and PZ plasma levels. CBC samples were measured using an automated cell counter, and PZ was assayed with an immunoassay method. Statistical analysis was conducted using SPSS software. The ROC curve and binary logistic regression estimated the sensitivity, specificity, and Odd’s ratio for PZ measurement.

RESULTS: The mean±SD of the PZ plasma level in normal individuals was 1.68±0.63 µg/mL, and in BTM patients, it was 1.10±0.52 µg/mL. This shows a significant reduction of PZ in BTM patients statistically (CI= 0.99; p<0.001). Further, the mean±SD of the PZ plasma levels in BTM patients who received washed red blood cells was not significantly different from that of patients undergoing packed red blood cell therapy (CI= 0.95; p = 0.320). The area under the curve (AUC) for PZ was 0.759 (p = 0.00). The cut-off value= 1.4 µg/mL of the PZ plasma level had at least 70% sensitivity and specificity in BTM patients.

DISCUSSION: Several epidemiologic studies have shown thromboembolism episodes in BTM patients. In the current study, PZ was reduced significantly in BTMs.

CONCLUSION: We noticed that BTMs have lower plasma PZ concentration might be predisposed to BTM.

Keywords

major beta-thalassemia / protein Z / thrombosis / immunoassay / anti-coagulation factor

References

[1] Al-Shanqeeti A, van Hylckama Vlieg  A, Berntorp E ,  Rosendaal F R ,  Broze G J Jr  (2005). Protein Z and protein Z-dependent protease inhibitor.Determinants of levels and risk of venous thrombosis. Thromb Haemost, 93(3): 411–413

[2] Alizadeh S, Bavarsad  M S, Dorgalaleh  A, Khatib Z K ,  Dargahi H ,  Nassiri N ,  Hamid F ,  Rahim F ,  Jaseb K ,  Saki N (2014). Frequency of beta-thalassemia or beta-hemoglobinopathycarriers simultaneously affected with alpha-thalassemia in Iran. Clin Lab, 60(6): 941–949

[3] Borgna-Pignatti C, Rugolotto  S, De Stefano P ,  Piga A, Di Gregorio  F, Gamberini M R ,  Sabato V ,  Melevendi C ,  Cappellini M D ,  Verlato G  (1998). Survival and disease complications in thalassemia major. Ann N Y Acad Sci, 850(1): 227–231

[4] Broze G J Jr ,  Miletich J P  (1984). Human Protein Z. J Clin Invest, 73(4): 933–938 160;

[5] Cappellini M D ,  Robbiolo L ,  Bottasso B M ,  Coppola R ,  Fiorelli G ,  Mannucci A P  (2000). Venous thromboembolism and hypercoagulability in splenectomized patientswith thalassaemia intermedia. Br J Haematol, 111(2): 467–473

[6] Cunningham M J ,  Macklin E A ,  Neufeld E J ,  Cohen A R , and the Thalassemia Clinical Research Network (2004). Complications of -thalassemia majorin North America. Blood, 104(1): 34–39 

[7] Eldor A, Rachmilewitz  E A (2002). The hypercoagulable state in thalassemia. Blood, 99(1): 36–43160;

[8] Elkhateeb M, Elmenshawy  I, Azzam H ,  Selim T ,  Abousamra N K ,  Elsharawy S  (2009). Plasma levels of protein Z and antiphospholipid protein antibodies in patientswith ischemic stroke. Egypt J Neurol PsychiatNeurosurg, 46(1): 11–17

[9] Gillis S, Cappellini  M D, Goldfarb  A, Ciceri L ,  Fiorelli G ,  Rachmilewitz E A  (1999). Pulmonary thromboembolism in thalassemia intermedia patients. Haematologica, 84(10): 959–960

[10] Gris J C, Quéré  I, Dechaud H ,  Mercier E ,  Pinçon C ,  Hoffet M ,  Vasse M ,  Marès P  (2002). High frequency of protein Z deficiency in patients withunexplained early fetal loss. Blood, 99(7): 2606–2608160;

[11] Han X, Fiehler  R, Broze G J Jr  (2000). Characterization of the protein Z-dependent protease inhibitor. Blood, 96(9): 3049–3055

[12] Han X, Huang  Z F, Fiehler  R, Broze G J Jr  (1999). The protein Z-dependent protease inhibitor is a serpin. Biochemistry, 38(34): 11073–11078 

[13] Hassan T H, Elbehedy  R M, Youssef  D M, Amr  G E (2010). Protein C levels in beta-thalassemiamajor patients in the east Nile delta of Egypt. Hematol Oncol Stem Cell Ther, 3(2): 60–65 

[14] Heeb M J, Paganini-Hill  A, Griffin J H ,  Fisher M  (2002). Low protein Z levels and risk of ischemic stroke: differences by diabetic status and gender. Blood Cells Mol Dis, 29(2): 139–144

[15] Kemkes-Matthes B, Matthes  K J (1995). Protein Z deficiency: a new cause of bleeding tendency. Thromb Res, 79(1): 49–55

[16] Kemkes-Matthes B, Nees  M, Kühnel G ,  Matzdorff A ,  Matthes K J (2002). Protein Z influences the prothrombotic phenotype inFactor V Leiden patients. Thromb Res, 106(4-5): 183–185 

[17] Kuypers F A, de Jong  K (2004). The role of phosphatidylserine in recognition and removalof erythrocytes. Cell Mol Biol (Noisy-le-grand), 50(2): 147–158

[18] Mendiratta S L ,  Mittal M ,  Naaz F, Singh  S, Anand S  (2017). Role of thalassemia screening in prevention and control of thalassemia-a5 year experience. Int J Reprod ContraceptObstet Gynecol, 5(9): 3107–3111

[19] Michaeli J, Mittelman  M, Grisaru D ,  Rachmilewitz E A  (1992). Thromboembolic complications in beta thalassemia major. Acta Haematol, 87(1-2): 71–74

[20] Miletich J P, Broze  G J J Jr (1987). Human plasma protein Z antigen: range in normal subjectsand effect of warfarin therapy. Blood, 69(6): 1580–1586

[21] Moratelli S, De Sanctis  V, Gemmati D ,  Serino M L ,  Mari R, Gamberini  M R, Scapoli  G L (1998). Thrombotic risk in thalassemic patients. J Pediatr Endocrinol Metab, 11(Suppl 3): 915–921

[22] Olivieri N F, Brittenham  G M (1997). Iron-chelating therapy and the treatment of thalassemia. Blood, 89(3): 739–761 

[23] Pardos-Gea J, Ordi-Ros  J, Serrano S ,  Balada E ,  Nicolau I ,  Vilardell M  (2008). Protein Z levels and anti-protein Z antibodies in patients with arterial andvenous thrombosis. Thromb Res, 121(6): 727–734

[24] Santacroce R, Sarno  M, Cappucci F ,  Sessa F ,  Colaizzo D ,  Brancaccio V ,  Grandone E ,  Margaglione M  (2006). Low protein Z levels and risk of occurrence of deep vein thrombosis. J Thromb Haemost, 4(11): 2417–2422

[25] Schettini F, De Mattia  D, Arcamone G ,  Sabato V ,  Altomare M ,  Burattini M G ,  Fedele F ,  Compagnone A ,  Ciavarella G  (1987). Coagulation contact phase factors and inhibitors in -thalassemia major children. Pediatr Hematol Oncol, 4(3): 231–236

[26] Singer S T, Kuypers  F A, Styles  L, Vichinsky E P ,  Foote D ,  Rosenfeld H  (2006). Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulablestate. Am J Hematol, 81(9): 670–675

[27] Steinberg M H  (2001). Disorders of hemoglobin: genetics, pathophysiology, and clinical management. J R Soc Med, 94(11): 602–603

[28] Vasse M, Guegan-Massardier  E, Borg J Y ,  Woimant F ,  Soria C  (2001). Frequency of protein Z deficiency in patients with ischaemic stroke. Lancet, 357(9260): 933–934 

[29] Weatherall D J  (1976). Molecular pathology of the thalassemia disorders. West J Med, 124(5): 388–402 

[30] Winichagoon P, Fucharoen  S, Wasi P  (1981). Increased circulating platelet aggregates in thalassaemia. Southeast Asian J Trop Med Public Health, 12(4): 556–560 

[31] Yin Z F, Huang  Z F, Cui  J, Fiehler R ,  Lasky N ,  Ginsburg D ,  Broze G J Jr  (2000). Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci USA, 97(12): 6734–6738 

Acknowledgements

We thank Shafa Hospital’s staffwho worked with us, and patients who were involved in this study.This work was performed under a grant from Ahvaz Jundishapur Universityof Medical Sciences.

Compliance with ethics guidelines

The authors declare no conflict of interest. All proceduresperformed in studies involving human participants were in accordancewith the ethical standards of the institutional and/or national researchcommittee and with the 1964 Helsinki declaration and its later amendmentsor comparable ethical standards.

RIGHTS & PERMISSIONS

2017 Higher Education Press and Springer-Verlag GmbH Germany, part of Springer Nature